Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance.
Fiche publication
Date publication
juin 2023
Journal
Diagnostics (Basel, Switzerland)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HOEFFEL Christine, Pr DELMER Alain
Tous les auteurs :
Durot C, Durot E, Mulé S, Morland D, Godard F, Quinquenel A, Delmer A, Soyer P, Hoeffel C
Lien Pubmed
Résumé
The purpose of this study was to determine whether texture analysis features present on pretreatment unenhanced computed tomography (CT) images, derived from 18F-fluorodeoxyglucose positron emission/computed tomography (18-FDG PET/CT), can predict progression-free survival (PFS), progression-free survival at 24 months (PFS 24), time to next treatment (TTNT), and overall survival in patients with high-tumor-burden follicular lymphoma treated with immunochemotherapy and rituximab maintenance. Seventy-two patients with follicular lymphoma were retrospectively included. Texture analysis was performed on unenhanced CT images extracted from 18-FDG PET/CT examinations that were obtained within one month before treatment. Skewness at a fine texture scale (SSF = 2) was an independent predictor of PFS (hazard ratio = 3.72 (95% CI: 1.15, 12.11), = 0.028), PFS 24 (hazard ratio = 13.38; 95% CI: 1.29, 138.13; = 0.029), and TTNT (hazard ratio = 5.11; 95% CI: 1.18, 22.13; = 0.029). Skewness values above -0.015 at SSF = 2 were significantly associated with lower PFS, PFS 24, and TTNT. Kurtosis without filtration was an independent predictor of PFS (SSF = 0; HR = 1.22 (95% CI: 1.04, 1.44), = 0.013), and TTNT (SSF = 0; hazard ratio = 1.23; 95% CI: 1.04, 1.46; = 0.013). This study shows that pretreatment unenhanced CT texture analysis-derived tumor skewness and kurtosis may be used as predictive biomarkers of PFS and TTNT in patients with high-tumor-burden follicular lymphoma treated with immunochemotherapy and rituximab maintenance.
Mots clés
X-ray computed, follicular lymphoma, positron emission tomography, tomography
Référence
Diagnostics (Basel). 2023 06 30;13(13):